LifeTech Capital Downgrades Marina Biotech To Neutral, $0.30 PT

Loading...
Loading...
LifeTech Capital downgraded its Marina Biotech
MRNA
rating from Strong Speculative Buy to Neutral and lowered its Marina Biotech price target from $2.50 to $0.30 in a research report published today. LifeTech Capital In the report, LifeTech Capital states, "Although Marina's announced financing is expected to yield much needed cash to the company (closing on or about May 20th), the terms result in significant dilution that adversely impacts projected earnings per share in our financial model beyond our projected dilution for future capital requirements." Shares of Marina Biotech were trading at $0.24 at the time of posting, down 3.08% from Tuesday's market close.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesPrice TargetAnalyst RatingsHealth CareLifeTech CapitalPharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...